Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 116 publications
Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma.
Journal: Research square
Published: April 27, 2026
Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration.
Journal: Cancer immunology research
Published: June 20, 2025
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.
Journal: The Journal of clinical investigation
Published: May 15, 2025
Lymphotropic Virotherapy Engages DC and High Endothelial Venule Inflammation to Mediate Cancer In Situ Vaccination.
Journal: medRxiv : the preprint server for health sciences
Published: May 02, 2025
Advances in neuro-oncology: contributions of the Asilomar Conference on brain tumor research and therapy.
Journal: Journal of neurosurgery
Published: December 20, 2024
Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.
Journal: SLAS discovery : advancing life sciences R & D
Published: December 10, 2023
The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study.
Journal: Journal of neurosurgery. Pediatrics
Published: October 09, 2023
Repurposing Clemastine to Target Glioblastoma Cell Stemness.
Journal: Cancers
Published: August 13, 2023
Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils.
Journal: Journal for immunotherapy of cancer
Published: March 30, 2023
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
Journal: Science translational medicine
Published: February 08, 2023
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Journal: Journal for immunotherapy of cancer
Published: December 13, 2022
Last Updated: 09/26/2026